Holen Sie sich die Stockscreener-App
9.16
1.08%
-0.10
Handel nachbörslich:
9.16
Schlusskurs vom Vortag:
$9.26
Offen:
$9.37
24-Stunden-Volumen:
492.37K
Relative Volume:
0.45
Marktkapitalisierung:
$969.91M
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-2.9644
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
+1.44%
1M Leistung:
+6.26%
6M Leistung:
-31.64%
1J Leistung:
-36.70%
1-Tages-Spanne:
$9.14
$9.46
1-Wochen-Bereich:
$9.09
$9.62
52-Wochen-Spanne:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
9.16 | 956.14M | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
What drives Arcus Biosciences Inc. stock priceExceptional gains - jammulinksnews.com
Is Arcus Biosciences Inc. a good long term investmentPhenomenal trading returns - jammulinksnews.com
Arcus Biosciences Inc. Stock Analysis and ForecastTriple-digit returns - jammulinksnews.com
What analysts say about Arcus Biosciences Inc. stockExplosive earning power - jammulinksnews.com
Teacher Retirement System of Texas Has $143,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Principal Financial Group Inc. Boosts Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Is Arcus Biosciences Inc. stock a good hedge against inflationFree Stock Investment Discussion Area - Newser
Trend Tracker for (RCUS) - news.stocktradersdaily.com
how arcus biosciences inc. stock performs during market volatilityTrending Stock Alert - Newser
How Arcus Biosciences Inc. stock performs during market volatilitySafe and Smart Investment Picks - Newser
What makes Arcus Biosciences Inc. stock price move sharplyFree Expert Investment Advice - Newser
Why Arcus Biosciences Inc. stock attracts strong analyst attentionElite Stock Shortlist - Newser
Allspring Global Investments Holdings LLC Has $144,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Allspring Global Investments Holdings LLC Purchases 6,453 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Amalgamated Bank Boosts Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus wins FDA orphan status for cancer drug (RCUS:NYSE) - Seeking Alpha
Arcus Biosciences' Investigational Pancreatic Cancer Treatment Gets US FDA Orphan Drug Status - MarketScreener
Arcus Biosciences' Quemliclustat Gets Orphan Drug Status For Pancreatic Cancer - Nasdaq
Arcus' Pancreatic Cancer Drug Gets FDA Orphan Status as Phase 3 Trial Nears Full Enrollment - Stock Titan
Does Arcus Biosciences (NYSE:RCUS) Have A Healthy Balance Sheet? - simplywall.st
Arcus Biosciences' Quemliclustat Receives Orphan Drug Designatio - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment - MSN
State of Alaska Department of Revenue Boosts Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
(RCUS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
GAMMA Investing LLC Buys 15,466 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: promising cancer therapy stock faces pivotal year - Investing.com
Arcus Biosciences Sees Unusually High Options Volume (NYSE:RCUS) - Defense World
Arcus Biosciences Holds Annual Stockholders Meeting - TipRanks
Arcus Biosciences Inc Inc. (RCUS) Price Performance: A Technical Analysis Perspective - investchronicle.com
Positive Signs As Multiple Insiders Buy Arcus Biosciences Stock - simplywall.st
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,872 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Comments on RCUS FY2026 Earnings - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News - GuruFocus
When the Price of (RCUS) Talks, People Listen - news.stocktradersdaily.com
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):